{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-038607","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2025-12-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.665370+00:00","generated_at":"2026-05-16T12:15:18.781701+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio Pharma gets FDA acceptance of PH-762 nonclinical study design; tox study Q1 2026","bullets":["FDA accepted nonclinical protocol study design for PH-762; toxicology study to begin Q1 2026.","Interim Phase 1b results: 6 complete responses among 16 evaluable cSCC patients; no dose-limiting toxicities.","Company advancing cGMP drug product delivery in 2026, partially funded by recent financing.","PH-762 well tolerated in all enrolled patients across five dose cohorts."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-038607","json":"https://secwatch.observer/filing/0001437749-25-038607.json","markdown":"https://secwatch.observer/filing/0001437749-25-038607.md","text":"https://secwatch.observer/filing/0001437749-25-038607.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925038607/0001437749-25-038607-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000143774925038607/phio20251222_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:15:18.781701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}